Antibodies and peptides in cancer therapy

Crit Rev Ther Drug Carrier Syst. 2006;23(5):401-35. doi: 10.1615/critrevtherdrugcarriersyst.v23.i5.20.

Abstract

Antibodies and peptides play a variety of roles in cancer therapy: monoclonal antibodies (mAbs) and peptides are directly used in anticancer therapy and also as targeting moieties. More than 10 mAbs, either unconjugated or in immunoconjugate forms have been approved for use in oncology. Various peptides, tumor necrosis factors (TNFs), and cell surface-targeted peptides have been identified using phage-display libraries. In combination with standard chemotherapeutic agents, mAbs and peptides can significantly increase the toxicity of anticancer drugs to tumors and reduce their adverse side effects on normal tissues. The present review summarizes some major applications of antibodies and peptides in cancer therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use
  • Drug Delivery Systems / methods
  • Humans
  • Immunotoxins / immunology
  • Immunotoxins / metabolism
  • Immunotoxins / therapeutic use
  • Molecular Structure
  • Neoplasms / diagnosis
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Peptides / administration & dosage
  • Peptides / chemistry
  • Peptides / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Cancer Vaccines
  • Immunotoxins
  • Peptides